Overview
SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that specifically concentrates in the inner mitochondrial membrane. Developed by Hazel Szeto at Weill Cornell Medical College, it is in advanced clinical trials for Barth syndrome, heart failure, and age-related mitochondrial dysfunction. It is one of the most clinically advanced anti-aging peptides.
Mechanism of action
SS-31 selectively binds to cardiolipin, a phospholipid unique to the inner mitochondrial membrane that is essential for electron transport chain (ETC) function. By stabilizing cardiolipin interactions with cytochrome c, SS-31 optimizes electron transfer, reduces electron leak and reactive oxygen species (ROS) production, and improves ATP synthesis. It concentrates 1000-5000x in mitochondria relative to cytoplasm due to its alternating aromatic-cationic structure.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| mitochondrial optimization | subcutaneous | 20–40 mg | daily | Clinical trial doses range from 4mg to 40mg daily. Limited availability outside clinical settings. 4-8 week cycles in research contexts. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Multiple clinical trials: Phase III for Barth syndrome (TAZPOWER), Phase II for heart failure (PROGRESS-HF), Phase II for age-related macular degeneration (ReCLAIM). Barth syndrome trial showed improvements in cardiac function and exercise tolerance. Animal studies demonstrate reversal of age-related mitochondrial dysfunction, improved cardiac function, kidney protection, and skeletal muscle recovery. Szeto's research shows reversal of age-related decline in mitochondrial function within hours of administration.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with SS-31 for synergistic effects.
Legal status
Investigational drug in clinical trials (Stealth BioTherapeutics). Not yet FDA-approved. Orphan drug designation for Barth syndrome. Not available as a standard research peptide from most suppliers.
Where to get it
Verified directory — coming soon
PeptaHub is building a verified supplier directory with third-party testing data, compliance status, and reader ratings.